[18F]FDG-PET/CT in DLBCL-patients treated with CAR-T cell therapy: potential for defining patient prognosis

Le résumé fourni par la source

Objectives The aim of this study is to evaluate the potential of [ 18 F]FDG-PET/CT in terms of prognostic value and treatment monitoring in relapsed / refractory diffuse large B-cell lymphoma (DLBCL)-patients treated with chimeric antigen receptor T-cell (CAR-T) therapy. Material & methods Forty-eight [ 18 F]FDG-PET/CT scans, acquired at pre-defined time points (t 0 – t 2 ) of 18 DLBCL-patients (mean age: 60 ± 12 years) treated with CAR-T cell therapy were retrospectively enrolled. Median time of follow-up was ten months (IQR 6–16) following CAR-T cell infusion. SUV max , sum of the product of diameters (SPD), Deauville score (DS) and Lugano classification (LC) were evaluated. Clinical parameters (age, sex) were obtained. Survival time analyses for progression-free survival (PFS) and overall survival (OS) were calculated, the latter by using the Kaplan-Meier method and Cox regression including a hazard ratio (HR). P values below 0.05 were defined as statistically significant. 95 %-confidence intervals (CI) were calculated. Results Patients with a SUV max > 9.0 at t 0 (median as threshold value) had a significantly shorter PFS ( p = 0.04) and OS ( p < 0.01). According to LC, a progressive disease (PD) at t 1 ( p = 0.02) and t 2 ( p < 0.01) was correlated with a reduced OS. SUV max > 9.0 at t 0 ( p = 0.03, HR=7.0, CI: 1.3–40.5) and DS > 3 at t 1 ( p = 0.04, HR=8.2, CI: 1.1–61.3) were associated with an increased risk of a PD. Conclusion SUV max of [ 18 F]FDG-PET/CT seems to be useful as a prognostic marker in DLBCL-patients undergoing CAR-T cell therapy. Furthermore, scores of clinical established Deauville classification and Lugano response criteria acquired at post-CAR-T [ 18 F]FDG-PET/CT might be an indicator for early therapy failure.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.